Our Focus

Supportive Care

Medicines that treat or manage secondary conditions arising from, relating to and complicated by underlying serious, chronic and long-term diseases.

Genito-Urinary Medicine

Medicines that treat or manage conditions related to sexual and reproductive health in both women and men.

Customer Care

Healthcare products that manage or treat common conditions that can be self-treated or managed with the assistance of healthcare professionals.

Our Expertise

Kora Healthcare is a fully integrated healthcare company with core competencies across Research, Development & Innovation, Scientific & Medical Affairs, Regulatory Affairs & Pharmacovigilance, Quality, Supply Chain, Marketing & Sales, Finance and Customer Services. All departments are led from our headquarters in Dublin, Ireland with UK sales and marketing operations located in York, UK.

Kora Healthcare is accredited and certified to Good Manufacturing Practice, Good Distribution Practice, ISO 13485 and holds a manufacturing license and wholesale license for product portfolio assets. Kora Healthcare operates under a virtual manufacturing platform in that Kora Healthcare manufactures through an established network of contract manufacturing organisations and contract research organisations for development and commercial manufacturing.

Kora Healthcare operates broadly along two business models:

Our ‘Home Markets’ model supported by our established infrastructure across the UK, Ireland and Germany involves a mix of internally developed portfolio products and in-licensed products.

Our ‘International Markets’ model, by contrast, is focussed on developing long-term licensee’s and distributors with a like-minded therapy focus across global markets, supported by our internal team.

As a business we are resourced and optimally-sized to delivery continued growth for several years from our portfolio of currently marketed products, coupled with multiple opportunities for continued geographical expansion anticipating the delivery on our product development pipeline. Our development pipeline builds on existing therapeutic areas of focus and lifestyle brands of the patients and consumers we serve.

Our current priorities include optimising the international market expansion of ready –to-market, Magnaspartate and increasing the global footprint of brands such as Relactagel and Regelle. Together with our international focus, we continue to ensure launch readiness for our ever-evolving research, development and innovation pipeline.

Contact Kora Healthcare:

Keep in touch with us and join our online community

Please tick the boxes to tell us if you would like to hear from us:

Yes, please I would like to receive communications by email from Kora Healthcare

 

The Kora Story

alt-text

Our Vision

At Kora Healthcare, we strive to build a sustainable, growth-orientated and value-driven business through delivery of a robust product portfolio and pipeline. By fostering a culture of innovation and quality, we will continue to anticipate, understand and respond to patient needs efficiently and effectively.

Leadership Team

The Kora Healthcare Leadership combines commercial and technical experience that spans decades of senior leadership across the pharmaceutical and medical device industry. By fostering a culture of innovation and quality our leadership team is focussed on building sustainable, growth-orientated and value-driven business.

We are seeking to engage with external partners, identify, develop and commercialise healthcare products international and to fully realise the potential and value of our established company infrastructure.

Conor O’Daly
Chief Executive Officer

Working with Kora Healthcare since 2010 across commercial functions, Conor O’Daly became a Chief Executive Officer in August 2016. Prior to joining Kora Healthcare, Conor worked with a then sister company to Kora Healthcare, Newport Pharmaceuticals. Conor holds a BA in International Business (Finance) with languages and subsequently completed a number of post-graduate diplomas across commercial disciplines. Conor also is an executive director on the Kora Healthcare Board of Directors.

Mark Blowers
Commercial Director (UK ethical)

Working with Kora Healthcare since 2009 Mark has over 30 years of pharmaceutical and nutrition industry experience. Mark strives to ensure maximum sales growth and long term return on investment for Kora UK and its product portfolio through the development and optimisation of its sales teams, marketing approaches and customer macro influencers.

Shane Fitzgerald
Commercial Director - ROI & ROW

Shane Fitzgerald is a life science graduate and pharmaceutical industry professional with many years of experience across multiple therapy classes. Shane has launched many new chemical entities, biologics and biosimilar agents in multiple international markets. Shane is insightful marketeer with a specific focus on market access solutions for new product launches, meeting the needs of patients, prescribers and payers. Committed to customer focus, Shane has keen focus on innovation, operational excellence and collaboration to improve clinical outcomes. Before coming to join Kora Healthcare, Shane enjoyed a successful career at many internal companies including, MSD Human Health Ireland, Pfizer Healthcare Ireland, Biogen Idec, and Servier Laboratories.

Eamonn McGowran
Head of Quality and Regulatory Affairs

Eamonn McGowran is a graduate of D.C.U. with a B.Sc and M.Sc in Biotechnology. He has amassed over 20 years experience within the pharmaceutical, biopharmaceutical, medical device, food and cosmetics arenas where he has developed a wide understanding of the global regulatory and quality needs to gain access to markets for both large and small organisations. He has previously worked for ICON PLC, Newport Pharmaceuticals, Quintiles, Mallinckrodt, IT works, Merus Labs and Klox Technologies where he had responsibilities for regulatory and compliance oversight of products at national and global levels.

Richard McGuinness 
Group Financial Controller

Richard was appointed the Financial Controller of Kora Corporation in 2019, where he oversees the accounting, financial planning, and analysis, treasury, audit and tax functions at Kora. He was Finance Director of 2468 Group from 2016 to 2019 where he was responsible for a Finance and M&A activity of the group. Prior to joining 2468 Richard worked in Bostik Industries and worked in a number of finance roles with Bostik from 2006 to 2016. He is a qualified accountant and holds a bachelors degree in Management Information Systems from St John Moore’s University Liverpool and a Professional Certificate in Management from Open University.

Natasha Bankowski
Regulatory & Pharmacovigilance Manager

Natasha has experience working in the Pharmaceutical and Medical Device Industry for over 10 years. She has worked across multiple areas including Quality Management, Regulatory Affairs, Medical Affairs, Pharmacovigilance and R&D. She has managed the Global Regulatory Affairs, Pharmacovigilance and Medical Affairs Departments and has been successful in building the global footpath with registrations in over 150 countries. Natasha holds a BSc in Medicinal Chemistry from Trinity College, Dublin and completed a further Higher Diploma in Pharmaceutical Production.

Sinead Healy
Scientific & Medical Affairs Manager

Sinead has responsibility for Development, Manufacturing Support and Medical Affairs at Kora Healthcare. Sinead worked for 10 years at Abbott Diagnostics in technical leadership roles in quality, product technical support and validation. Sinead also worked as a Cell Culture Manager, responsible for the upstream commercial production of recombinant Follicle Stimulating Hormone (FSH). Sinead graduated with a degree in Industrial Biochemistry from the University of Limerick and earned a Ph.D. in Cell Biology /Immunology from Trinity College Dublin, and went on to work as a post-doctoral researcher in the areas of colon cancer and asthma.

Annette Dolan
Quality Manager

Annette holds a B.Sc in Industrial Biology, Higher Diploma in Pharmaceutical production and Food Science, Annette has 20 years experience across Medical Device and Pharmaceutical Industry and gained valuable experience while working in a number of areas including Analytical Chemistry, Validation and Quality before joining the Quality team at Kora in 2015. Annette has previously worked in Multi-national organisations including Pfizer, MSD, Leo Pharma and BD Medical bringing a wide range of varied experience to the management of the Quality System at Kora. Green Belt Certified and Lead Auditor trained Annette has successfully lead a number of Notified Body Audits at Kora.

Alaa Ghazy
Research and Development Manager

Alaa oversees the Research and Development Department in Kora Healthcare, responsible for New Product Introduction and ongoing Manufacturing support. Alaa has over 10 years’ experience working in the Pharmaceutical Industry in the United Kingdom, Ireland and the Middle east. She has worked across R&D, Project Management, Process, and Technical departments. Alaa holds a BSc in Pharmacy, and is a Pharmaceutical Scientist member of the British Royal Pharmaceutical Society. Alaa has also completed a post graduate diploma in Total Quality Management and Quality Management System, and a diploma in Organic skincare formulations.

Board of Directors

The Kora Healthcare Board of Directors provides the leadership, guidance and governance necessary to execute our mission, vision and strategy now and into the future.

  • Darren Cunningham | Chairman

  • Joan O’Daly | Director 

  • Shauna Lord | Non-Executive Director

  • Clodagh Kelly | Non-Executive Director

  • Conor O’Daly | Executive Director

Immdal Group

Immcell

Kora Healthcare is a 100% privately owned healthcare company and a subsidiary of Immdal Ltd Group.

The Immdal Ltd Group consists of Kora Healthcare and Immcell Ltd, a sister company to Kora Healthcare, and is wholly owned by the O’Daly family. Immdal Ltd seeks to develop additional commercial subsidiaries with growth potential capable of delivering regular income and profits to the group including but not limited to; biotechnology, finished pharmaceuticals, novel technology platform, active ingredients across both food and pharmaceuticals, animal health, bio-marine products, renewable and sustainable energies and commercial property.

Visit the Immcell website